ArticleMolecular cancer therapeutics2008

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Tadas Vasaitis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.